Heart Rate-Corrected QT Interval Helps Predict Mortality after Intentional Organophosphate Poisoning by Liu, Shou-Hsuan et al.
Heart Rate-Corrected QT Interval Helps Predict Mortality
after Intentional Organophosphate Poisoning
Shou-Hsuan Liu, Ja-Liang Lin, Cheng-Hao Weng, Huang-Yu Yang, Ching-Wei Hsu, Kuan-Hsing Chen,
Wen-Hung Huang, Tzung-Hai Yen*
Division of Clinical Toxicology, Department of Nephrology, Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taipei, Taiwan
Abstract
Introduction: In this study, we investigated the outcomes for patients with intentional organophosphate poisoning.
Previous reports indicate that in contrast to normal heart rate-corrected QT intervals (QTc), QTc prolongation might be
indicative of a poor prognosis for patients exposed to organophosphates.
Methods: We analyzed the records of 118 patients who were referred to Chang Gung Memorial Hospital for management of
organophosphate poisoning between 2000 and 2011. Patients were grouped according to their initial QTc interval, i.e.,
normal (,0.44 s) or prolonged (.0.44 s). Demographic, clinical, laboratory, and mortality data were obtained for analysis.
Results: The incidence of hypotension in patients with prolonged QTc intervals was higher than that in the patients with
normal QTc intervals (P=0.019). By the end of the study, 18 of 118 (15.2%) patients had died, including 3 of 75 (4.0%)
patients with normal QTc intervals and 15 of 43 (34.9%) patients with prolonged QTc intervals. Using multivariate-Cox-
regression analysis, we found that hypotension (OR=10.930, 95% CI=2.961–40.345, P=0.000), respiratory failure
(OR=4.867, 95% CI=1.062–22.301, P=0.042), coma (OR=3.482, 95% CI=1.184–10.238, P=0.023), and QTc prolongation
(OR=7.459, 95% CI=2.053–27.099, P=0.002) were significant risk factors for mortality. Furthermore, it was revealed that
non-survivors not only had longer QTc interval (503.00641.56 versus 432.71651.21 ms, P=0.002), but also suffered higher
incidences of hypotension (83.3 versus 12.0%, P=0.000), shortness of breath (64 versus 94.4%, P=0.010), bronchorrhea (55
versus 94.4%, P=0.002), bronchospasm (50.0 versus 94.4%, P=0.000), respiratory failure (94.4 versus 43.0%, P=0.000) and
coma (66.7 versus 11.0%, P=0.000) than survivors. Finally, Kaplan-Meier analysis demonstrated that cumulative mortality
was higher among patients with prolonged QTc intervals than among those with normal QTc intervals (Log-rank test, Chi-
square test=20.36, P,0.001).
Conclusions: QTc interval helps predict mortality after intentional organophosphate poisoning.
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Introduction
Accidental or intentional ingestion of pesticides or herbicides is
common in Taiwan because these poisons are easily accessible [1].
In a nationwide study [2], all 4799 organophosphate poisonings
reported to Taiwan’s Poison Control Centers between July 1985
and December 2006 were reviewed. Most organophosphate
exposures were to a single organophosphate (80.37%) and nearly
all were acute (98.37%). Ingestion was the most common route of
exposure (74.50%), and attempted suicide (64.72%) was the most
common reason given for exposure. Most of the reported exposure
occurred in adults (93.25%) and males were more commonly
exposed than females (64.95%). Most patients (61.97%) received
atropine and/or pralidoxime. The mortality rate for all 4799
organophosphate poisonings was 12.71% [2].
There are 3 distinct clinical syndromes after acute organophos-
phate poisoning [3]: (1) acute cholinergic crisis (,0.5 d) as a result
of acetylcholinesterase inhibition, (2) an intermediate syndrome
(0.5–7 d) that has an underlying mechanism that is still unclear,
and (3) delayed neuropathy (6–21 d) that is explained by the
inhibition of neuropathy-target esterase. Acute cholinergic crisis
[3] includes signs and symptoms resulting from hyperstimulation
of muscarinic receptors (e.g., bradycardia, bronchoconstriction,
bronchorrhea, hypotension, increased gastrointestinal motility,
abdominal cramps, miosis, hypersalivation), nicotinic receptors
(e.g., hypertension, tachycardia, fibrillation, fasciculation, necrosis
of striated muscles), and both central muscarinic and nicotinic
receptors (e.g., tremor, movement incoordination, seizures, central
depression of respiration, coma, death). The intermediate
syndrome [4] is characterized by the onset of proximal muscle
weakness and cranial nerve palsies. Difficulty in breathing may
progress to respiratory failure due to paralysis of the diaphragm
and other muscles of respiration. Delayed polyneuropathy [4]
predominantly affects the long nerves or tracts in the nervous
system, causing symmetrical weakness of peripheral muscles in the
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impairment.
The cardiac complications associated with organophosphate
poisoning are not fully appreciated by many medical practitioners.
Organophosphate poisoning may precipitate complex ventricular
arrhythmias, a frequently overlooked and potentially lethal aspect
of this condition [5]. The mechanism by which organophosphates
induce cardiotoxicity is still uncertain. In 1982, Ludomirsky et al
[6] described 3 phases of cardiac toxicity after organophosphate
poisoning: phase 1, a brief period of increased sympathetic tone;
phase 2, a prolonged period of parasympathetic activity; and phase
3, in which QT prolongation is followed by torsade de pointes
ventricular tachycardia and ventricular fibrillation [6]. The long
QT-interval syndrome is believed to originate from intense and
unequal sympathetic stimulation of myocardial fibers. QT-interval
prolongation has been observed in some cases of severe
bradycardia or disease of the central nervous system. Therefore,
both sympathetic and parasympathetic overactivity may cause
QT-interval prolongation, and it is not surprising to find QT-
interval prolongation in cases of severe organophosphate poison-
ing.
In a preliminary study at Chang Gung Memorial Hospital [7],
Chuang et al reported that patients with QTc prolongation had a
higher mortality rate (19.6% vs. 4.8%, P,0.001) and a higher
incidence of respiratory failure (56.7% vs. 20.6%, P,0.001) than
patients without QTc prolongation. However, the data was not
examined using Cox proportional hazard models, so analysis of
multiple risk factors was not possible. Therefore, in this study, we
investigated the clinical features, QTc interval, physiological
markers, and clinical outcomes of Taiwanese patients after
intentional organophosphate poisoning. We determined what
association, if any, exists between these variables. Most impor-
tantly, we evaluated QTc interval prolongation as a predictor of
mortality after organophosphate poisoning.
Materials and Methods
This retrospective observational study complied with the
guidelines of the Declaration of Helsinki and approved by the
Medical Ethics Committee of Chang Gung Memorial Hospital, a
tertiary referral center located in the northern part of Taiwan.
Since this study involved retrospective review of existing data, the
Institutional Review Board approval was obtained, but without
specific informed consent from patients. However, the informed
consent of risk of acute organophosphate poisoning and all
treatment modalities (including cardiopulmonary cerebral resus-
citation, etc) were obtained from all patients on their initial
admission. In addition, all individual information was securely
protected (by delinking identifying information from main data set)
and available to investigators only. Furthermore, all the data were
analyzed anonymously. On the other hand, if this study involved
retrospective review of existing data plus retrospective analysis of
remaining biological samples, both Institutional Review Board
approval and specific informed consent must be obtained from all
patients. The Institutional Review Board of Chang Gung
Memorial Hospital has specifically waived the need for consent.
Finally, all primary data were collected according to strengthening
the reporting of observational studies in epidemiology guidelines.
Patients
We analyzed the records of 118 patients with intentional
organophosphate poisoning who were examined at Chang Gung
Memorial Hospital between 2000 and 2011. Diagnosis of
organophosphate poisoning was based on history of exposure,
clinical effects, and serum cholinesterase activity. Blood cholines-
terase activity was determined using an enzymatic method (normal
values, 7–19 U/mL) immediately after patient arrival at the
hospital. The pesticide involved was determined by history,
container label, or product information provided by the patient.
A complete clinical profile of each patient was recorded using a
standardized form. We obtained the following data for each
patient: age, sex, blood pressure, heart rate, type and toxicity
classification of organophosphate, underlying diseases, smoking
habits, alcohol consumption, use of medications that might be
associated with QTc-prolongation, time elapsed between poison-
ing and arrival at the hospital, duration of follow-up, clinical
manifestations, electrocardiogram results, blood cholinesterase
level, hemogram, biochemistry, detoxification protocol used, and
mortality. The electrocardiogram recordings were obtained upon
arrival at the emergency department. Of the 118 patients, there
were 75 patients with normal (,0.44 s) QTc intervals, and 43
patients with prolonged (.0.44 s) QTc intervals.
Inclusion and exclusion criteria
All patients older than 18 years of age who were diagnosed with
organophosphate poisoning at Chang Gung Memorial Hospital
between 2000 and 2011 were eligible for inclusion in this study.
Patients were excluded from this study if they were younger than
18 years of age or did not have low blood cholinesterase levels
despite suspicions of exposure.
Detoxification protocols
The protocols used to treat patients included gastric lavage with
large amounts of normal saline, followed by infusion of 1 g/kg
activated charcoal and 250 mL magnesium citrate via nasogastric
tube. Magnesium citrate was used to prevent constipation after
charcoal administration. Patients were also treated with specific
antidotes that included atropine and oximes. Intravenous atropine
was administered at a starting dose of 2 mg every 1–2 h, and
dosing was titrated to the clearing of respiratory secretions and
cessation of bronchoconstriction. Pralidoxime therapy (1 g every
4 h, intravenous) was also given to all patients with evidence of
cholinergic toxicity.
Definition of clinical events
Classification of organophosphate toxicity followed formal
World Health Organization recommendations: Ia, extremely
hazardous; Ib, highly hazardous; II, moderately hazardous; III,
slightly hazardous; and U, unlikely to present acute hazard [8].
Acute renal failure was diagnosed if serum creatinine level
increased to greater than 1.27 mg/dL in males or 1.03 mg/dL
in females. Acute respiratory failure was defined as a condition of
respiratory insufficiency requiring intubation and mechanical
ventilation for more than 24 h, regardless of the fraction of
inspired oxygen [9]. Hypotension was defined as a systolic blood
pressure of less than 90 mmHg [10]. Structural heart disease was
defined as non-coronary cardiovascular disease processes and
related interventions [11]. Uses of medications that might be
associated with QTc-prolongation were recorded. In this regard,
the anti-arrhythmic agents included class Ia, class Ic, and class III
agents [12]. The anti-microbials include macrolides/ketolides,
certain fluoroquinolones, certain anti-malarials, pentamidine and
azole anti-fungals [13]. The anti-psychotics and antidepressants
included a) typical anti-psychotics such as chlorpromazine,
pimozide, thioridazine, perphenazine, trifluoperazine, haloperidol,
and droperidol; b) atypical anti-psychotics such clozapine,
quetiapine, risperidone, sultopride, ziprasidone, and loxapine; c)
tricyclic anti-depressants such as amitryptyline, amoxapine,
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nortryptyline, and trimipramine; and d) other anti-depressants
such as fluoxetine, sertraline, and venlafaxine [14].
Statistical analysis
Continuous variables are expressed as means and standard
deviations and categorical variables as numbers with percentages
in brackets. All data were tested for normality of distribution and
equality of standard deviations before analysis. For comparisons
between patient groups, we used Student’s t test for quantitative
variables and Chi-square or Fisher’s exact tests for categorical
variables. Mortality data were compared using the Kaplan-Meier
method and significance was tested using a log-rank test. An initial
univariate Cox regression analysis was performed to compare the
frequency of possible risk factors associated with mortality. To
control for possible confounding factors, a multivariate Cox
regression analysis (stepwise backward approach) was performed
to analyze those factors that were significant in univariate models
Table 1. Baseline characteristics of patients with organophosphate poisoning (N=118).
Variable Normal QTc (N=75) Prolonged QTc (N=43) P
QT interval, ms 323.26642.32 390.65651.15 0.000
QTc interval, ms 411.13616.76 500.35635.52 0.000
Age, years 52.04616.94 56.37614.65 0.163
Male, n (%) 52 (69.3) 25 (58.1) 0.219
Organophosphate type, n (%) 0.466
Mevinphos 6 (8.0) 4 (9.3)
Parathion 3 (4.0) 1 (2.3)
Phorate 1 (1.3) 0 (0.0)
Terbufos 1 (1.3) 1 (2.3)
Dichlorvos 1 (1.3) 0 (0.0)
Fenamiphos 1 (1.3) 0 (0.0)
Methamidophos 10 (13.3) 4 (9.3)
Chlorpyrifos 31 (41.3) 17 (39.5)
Dimethoate 3 (4.0) 6 (14.0)
Profenofos 8 (10.7) 8 (18.6)
Trichlorfon 3 (4.0) 0 (0.0)
Acephate 2 (2.7) 1 (2.3)
Malathion 5 (6.7) 1 (2.3)
Organophosphate toxicity, n (%) 0.509
Ia Extremely hazardous 11 (14.7) 6 (14.0)
Ib Highly hazardous 12 (16.0) 4 (9.3)
II Moderately hazardous 45 (60.0) 31 (72.1)
III Slightly hazardous 7 (9.3) 2 (4.7)
U Unlikely to present acute hazard 0 (0) 0 (0)
Hypertension, n (%) 14 (18.7) 7 (16.3) 0.744
Old stroke, n (%) 7 (9.3) 3 (7.0) 0.658
Coronary artery disease, n (%) 1 (1.3) 2 (4.7) 0.270
Structural heart disease, n (%) 5 (6.7) 6 (14.0) 0.190
Chronic obstructive pulmonary disease, n (%) 4 (5.3) 5 (11.6) 0.215
Malignancy, n (%) 1 (1.3) 2 (4.7) 0.270
Mental disorder, n (%) 34 (45.3) 17 (39.5) 0.541
Smoking habit, n (%) 31 (41.3) 21 (48.8) 0.429
Alcohol consumption, n (%) 30 (40.0) 19 (44.2) 0.657
Use of medications that might be associated with QTc-
prolongation
Anti-arrhythmic agents, n (%) 13 (17.63) 7 (16.3) 0.883
Anti-psychotics and anti-depressants, n (%) 20 (26.7) 10 (23.3) 0.682
Anti-microbials, n (%) 6 (8.0) 4 (9.3) 0.807
Time from poisoning to hospital, hour 6.29614.05 4.4864.70 0.413
Duration of follow-up, months 18.43633.21 7.76621.27 0.061
doi:10.1371/journal.pone.0036576.t001
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model. We considered results that rejected the null hypothesis with
95% confidence to be significant. All analyses were performed
using SPSS 12.0 for Windows (SPSS Inc., Chicago, Illinois, USA).
Results
Baseline characteristics
Table 1 shows the baseline characteristics of the 118 patients
with organophosphate poisoning, grouped according to QTc
Table 2. Clinical manifestations of patients with organophosphate poisoning (N=118).
Variable Normal QTc (N=75) Prolonged QTc (N=43) P
1. Cholinergic crisis
Cardiovascular system:
Systolic blood pressure, mmHg 122.40618.54 107.05627.23 0.000
Diastolic blood pressure, mmHg 84.01614.57 72.12621.47 0.001
Heart rate, beats per minute 77.1569.40 85.28641.77 0.108
Hypotension, n (%) 12 (16.0) 15 (34.9) 0.019
Gastrointestinal system:
Diarrhea, n (%) 21 (28.0) 14 (32.6) 0.602
Emesis, n (%) 22 (29.3) 20 (46.5) 0.061
Respiratory system:
Shortness of breath 47 (62.7) 34 (79.1) 0.065
Bronchorrhea 41 (54.7) 31 (72.1) 0.062
Bronchospasm 38 (50.7) 29 (67.4) 0.077
Respiratory failure, n (%) 34 (45.3) 26 (60.5) 0.114
Genitourinary system:
Acute renal failure, n (%) 5 (6.7) 6 (14.0) 0.190
Central nervous system:
Seizure, n (%) 6 (8.0) 4 (9.3) 0.807
Coma, n (%) 11 (14.7) 12 (27.9) 0.081
2. Intermediate syndrome, n (%) 6 (8.0) 4 (9.3) 0.807
3. Delay neuropathy, n (%) 1 (1.3) 2 (4.7) 0.270
doi:10.1371/journal.pone.0036576.t002
Table 3. Laboratory analysis of blood from patients with organophosphate poisoning (N=118).
Variable Normal QTc (N=75) Prolonged QTc (N=43) P
Hemoglobin, g/dL 14.2462.06 14.3461.63 0.770
Blood urea nitrogen, mg/dL 17.07620.12 15.8966.09 0.775
Creatinine, mg/dL 1.0660.83 1.0260.40 0.811
Sodium, mEq/L 140.8863.11 141.2164.31 0.644
Potassium, mEq/L 3.6060.54 3.4160.49 0.071
Calcium, mg/dL 8.7860.60 8.5360.57 0.342
Cholinesterase, initial, U/mL 3.5863.37 2.9063.59 0.299
Cholinesterase, lowest, U/mL 2.9562.90 2.3563.20 0.298
C-reactive protein, mg/dL 9.30620.31 6.1765.90 0.700
Amylase, U/L 147.626126.05 276.186245.99 0.113
Lipase, U/L 117.00695.11 105.00660.03 0.780
CK-MB, ng/mL 11.3766.75 28.89660.65 0.376
Troponin-I, ng/mL 0.0960.11 0.0660.09 0.411
doi:10.1371/journal.pone.0036576.t003
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between groups.
Respiratory symptoms were common after organophosphate
poisoning (Table 2). Further, there were more cases of hypotension
among these patients than among those with normal QTc interval
(P=0.019). Patients with prolonged QTc interval had lower
systolic (P=0.000) and diastolic (P=0.001) blood pressure than
patients with normal QTc interval. No other clinical (Table 2) or
laboratory (Table 3) variables differed between groups.
As shown in Table 4, most patients were treated aggressively
with gastric lavage of large amounts of normal saline, followed by
an infusion of 1 g/kg activated charcoal and 250 mL magnesium
citrate. In addition, nearly all patients were treated with systemic
atropine and pralidoxime injections. There was no difference in
treatment modality between groups.
By the end of this study, 18 of 118 (15.2%) patients had died,
including 3 of 75 (4.0%) patients with normal QTc interval and 15
of 43 (34.9%) patients with prolonged QTc interval. Regarding
the causes of mortality (Table 4), one patient from normal QTc
interval died of cardiac arrhythmia, one died of respiratory failure,
and one died of sepsis. On the other hand, 9 patients from
prolonged QTc interval died of cardiac arrhythmia, 5 died of
respiratory failure, and one died of sepsis. This difference was not
significant (P=0.383), probably due to the small sample size.
Multivariate Cox regression analysis revealed that hypotension
(odds ratio (OR)=10.930, 95% confidence interval (CI)=2.961–
40.345, P=0.000), respiratory failure (OR=4.867, 95%
CI=1.062–22.301, P=0.042), coma (OR=3.482, 95%
CI=1.184–10.238, P=0.023), and QTc prolongation
(OR=7.459, 95% CI=2.053–27.099, P=0.002) were significant
risk factors for mortality (Table 5). Finally, Kaplan-Meier analysis
demonstrated that cumulative mortality was higher among
patients with prolonged QTc intervals than among those with
normal QTc intervals (Figure 1, Log-rank test, Chi-square
test=20.36, P,0.001).
A direct comparison between non-survivors and survivors
(Table S1) revealed that non-survivors not only had longer QTc
interval (503.00641.56 versus 432.71651.21 ms, P=0.002), but
also suffered higher incidences of hypotension (83.3 versus 12.0%,
P=0.000), shortness of breath (64 versus 94.4%, P=0.010),
bronchorrhea (55 versus 94.4%, P=0.002), bronchospasm (50.0
versus 94.4%, P=0.000), respiratory failure (94.4 versus 43.0%,
P=0.000) and coma (66.7 versus 11.0%, P=0.000) than survivors.
Furthermore, the systolic (P=0.000) and diastolic (P=0.000)
blood pressure was lower, but heart rate (P=0.005) was higher in
non-survivors than survivors.
Discussion
It has been well demonstrated that QT-interval prolongation
affects mortality rate in the general population [15]. QT-interval
prolongation also affects the mortality rates of patients with a
variety of diseases, including end-stage renal disease [16], coronary
artery disease, congestive heart failure [17], diabetes mellitus [18],
acute ischemic stroke [19], chronic liver disease [20], and chronic
obstructive pulmonary disease [21]. Using a multivariate Cox
regression model, we have demonstrated in this study that QTc
interval prolongation might be an important risk factor for
mortality after intentional organophosphate poisoning.
The relationship between QTc interval prolongation and
subsequent mortality after organophosphate poisoning remains
uncertain (Table 6). Baydin et al [22] reported that 35.4% of the
20 Turkish patients studied presented with prolonged QTc
Table 4. Detoxification protocol and outcome for patients with organophosphate poisoning (N=118).
Variable Normal QTc (N=75) Prolonged QTc (N=43) P
Gastric lavage, n (%) 58 (77.3) 37 (86.0) 0.250
Active charcoal and magnesium
citrate, n (%)
55 (73.3) 33 (76.7) 0.682
Atropine, n (%) 74 (98.7) 42 (97.7) 0.688
Pralidoxime, n (%) 73 (97.3) 42 (97.7) 0.910
Mortality, n (%) 3 (4.0) 15 (34.9) 0.000
Causes of mortality, n (%) 0.383
Cardiac arrhythmia 1 (33.3) 9 (60.0)
Respiratory failure 1 (33.3) 5 (33.3)
Sepsis 1 (33.3) 1 (6.7)
doi:10.1371/journal.pone.0036576.t004
Table 5. Univariate and multivariate Cox regression analysis for mortality (N=118).
Variable
Univariate analysis
OR (95% CI) P
Multivariate analysis
OR (95% CI) P
Hypotension 21.596 (6.237–74.780) 0.000 10.930 (2.961–40.345) 0.000
Respiratory failure 8.504 (1.955–36.997) 0.004 4.867 (1.062–22.301) 0.042
Coma 10.317 (3.857–27.595) 0.000 3.482 (1.184–10.238) 0.023
QTc prolongation 9.974 (2.885–34.478) 0.000 7.459 (2.053–27.099) 0.002
Note: OR odds ratio, CI confidence interval.
doi:10.1371/journal.pone.0036576.t005
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interval and blood cholinesterase level. In a study of 13 Indian
patients who died of organophosphate poisoning, Annad et al [23]
found 4 with episodic tachycardia and ST-T changes, 3 with QT
prolongation, and 2 with episodic bradycardia. On autopsy, all 13
patients had myocardial interstitial edema and vascular conges-
tion, while 8 had patchy interstitial inflammation, 2 had patchy
myocarditis, and 6 had a mural thrombus. Yurumez et al [24]
analyzed the records of 85 Turkish patients with organophosphate
poisoning and found that 47 patients (55.5%) had a prolonged
QTc interval. Only 2 patients died in this study (2.4%), and no
QTc prolongation was found in either patient (QTc intervals:
0.44 s and 0.40 s). The authors therefore concluded that QTc
interval prolongation could not be used as a unique predictive
factor in determining short-term mortality in their study [24]. In
contrast, Shadnia et al [25] reported that the mortality rate of
Iranian patients with long QTc intervals was significantly higher
than that of those with normal QTc intervals. In a subsequent
study, Akdur et al [26] found that 26 of 54 (53.7%) Turkish
patients had prolonged QTc intervals. However, no significant
correlation was found between poisoning severity and QTc
interval. More recently [27], Vijayakumar evaluated 20 Indian
patients with organophosphate poisoning and discovered that 12
patients (60.0%) had prolonged QTc intervals. However, the
predictive power of QTc interval prolongation on subsequent
mortality was not explored.
In this study, we found that patients with QTc-interval
prolongation were slightly older than those with normal QTc
intervals despite not reaching the level of statistical significance
(56.37614.65 versus 52.04616.94, P=0.163). In a longitudinal
Table 6. Summary of published studies reporting a possible association between QTc and mortality rate after organophosphate
poisoning.








1996 [7] Taiwan 223 25 (11.2) 43.5 Yes
2007 [22] Turkey 20 2 (10) 35.4
2009 [23] India 36 13 (36.1) 23.1
2009 [24] Turkey 85 2 (2.4) 55.5 No
2009 [25] Iran 42 15 (37.5) 59.5 Yes
2010 [26] Turkey 54 3 (5.6) 48.1 No
2011 [27] India 20 60.0
2012 Current study Taiwan 118 18 (15.2) 36.4 Yes
doi:10.1371/journal.pone.0036576.t006
Figure 1. Kaplan-Meier analysis of data from patients with organophosphate poisoning, grouped according to the duration of the
QTc interval. Patients with prolonged QTc intervals suffered higher cumulative mortality than patients with normal QTc intervals (Log-rank test, Chi-
square test=20.36, P,0.001).
doi:10.1371/journal.pone.0036576.g001
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significantly with age in a population of healthy elderly subjects.
Elderly hearts tend to have relative midmyocardial myocyte
hypertrophy and a distinct increase in connective tissue as
compared to younger hearts [29]. Myocyte hypertrophy may be
associated with a significant prolongation of the transmembrane
action potential, explaining the prolongation of the QTc interval
[30] with age. There are also reports of an exaggerated shift
towards sympathetic activity in the elderly [31], and such
sympathetic overactivity might be an important factor in the
prolongation of the QT interval. Therefore, it is not surprising to
find longer QT intervals among elderly patients with organophos-
phate poisoning than among younger organophosphate poisoning
patients.
As shown in Table 1 and 2, there was a trend that the patients
in the group with prolonged QTc were older (P=0.163). It is
possible that the increased mortality in this group might due to the
age and or age-related diseases like chronic obstructive pulmonary
disease and coronary artery disease. The data in the present study
also showed a trend of higher percentage of patients with chronic
obstructive pulmonary disease (P=0.215), structural heart disease
(P=0.190), and coronary artery disease (P=0.270) in the group
with prolonged QTc although not reaching the level of statistical
significance due to the small numbers. This group of patient also
had a trend of increased frequencies in developing hypotension
(P=0.019), and respiratory distress like shortness of breath
(P=0.065), bronchorrhea (P=0.062), bronchospasm (P=0.077),
and respiratory failure (P=0.114). The patients in prolonged QTc
group also had a trend of increased renal failure (P=0.190) as
well. Nevertheless, a direct comparison between non-survivors and
survivors (Supporting Information Table S1) revealed that non-
survivors not only had longer QTc interval (P=0.002), but also
suffered higher incidences of hypotension (P=0.000), shortness of
breath (P=0.010), bronchorrhea (P=0.002), bronchospasm
(P=0.000), respiratory failure (P=0.000) and coma (P=0.000)
than survivors. Therefore, further large-scale study is necessary to
delineate the associations between the clinical features, QTc
interval, physiological markers, and clinical outcomes of patients
with organophosphate poisoning.
Finally, multivariate Cox regression analysis confirmed that
hypotension (P=0.000), respiratory failure (P=0.042), coma
(P=0.023), and QTc prolongation (P=0.002) were significant
risk factors for mortality after organophosphate poisoning. The
associations between both hypotension [32] and coma with
mortality are not surprising, because both are important vital
signs, irrespective of the cause of disease. Similarly, it is not
surprising to find an association between respiratory failure and
mortality because respiratory failure is a prominent feature of
acute organophosphate poisoning with an early central apnea
followed by later pulmonary effects [33]. Laboratory studies also
support the idea that organophosphate-induced respiratory failure
results from local effects of organophosphates acting on brainstem
circuits underlying respiratory rhythmogenesis, and on lung tissues
underlying pulmonary secretory, airway and vascular function
[33]. Furthermore, Chuang et al [7] also confirmed in their study
that patients with QTc prolongation had a higher mortality rate
and a higher incidence of respiratory failure than patients without
QTc prolongation.
In summary, QTc interval helps predict mortality after
intentional organophosphate poisoning. However, the retrospec-
tive nature of the study, small patient population, absence of
routine serum magnesium measurement, and lack of serial
electrocardiogram recordings limit the certainty of our conclu-
sions.
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